Kemwell Biopharma

What Kemwell Biopharma does

Kemwell Biopharma Private Limited is a Bengaluru, India-based biologics contract development and manufacturing organization (CDMO) that provides end-to-end services for mammalian cell-culture-based protein therapeutics. The company operates from a dedicated biologics campus featuring over 5,000L of installed bioreactor capacity across hybrid stainless steel and single-use bioreactor systems (80L to 2,000L scale), with capabilities spanning upstream process development, downstream purification, formulation, analytical method development, cGMP drug substance manufacturing, and cGMP drug product manufacturing including liquid vials, lyophilized vials, and pre-filled syringes. The company is licensed by India's CDSCO and holds US FDA, EMA, and Malaysia NPRA (PIC/S) accreditations, with its first US FDA pre-approval inspection for commercial drug product manufacturing completed in October 2025. Service offerings cover monoclonal antibodies, bi-specific and multi-specific antibodies, fusion proteins, recombinant proteins, biosimilars, and cell therapies. Notable proprietary capabilities include the Ambr 250 high-throughput process development platform, high-concentration tangential flow filtration (>200 mg/mL), SEC-HPLC methods for tri-specific antibody analysis, and India's first cGMP cell therapy manufacturing capability operated by a CDMO.

Kemwell operates as a pure-play B2B CDMO with project-based contracts to global pharmaceutical and biotech customers. The company is led by Chairman and CEO Anurag Bagaria and Managing Director Karan Bagaria, and is supported by a workforce in the 1001-5000 employee band. Its go-to-market is enterprise-focused, relying on direct engagement, industry conferences (JPM Healthcare Conference, Bio Europe, Bio International), and long sales cycles involving technical evaluation, regulatory compliance assessment, and custom contract negotiation. Revenue is generated through professional services contracts for development, clinical manufacturing, and commercial supply, with pricing not publicly disclosed. Operational performance metrics reported by the company include >95% on-time-in-full delivery, >98% right-first-time manufacturing, 100% drug product lot acceptance, and >97% drug substance lot acceptance, with over 40 customer audits completed and 20+ commercial batches of a globally approved monoclonal antibody supplied at 2,000L scale.

The company's strategic posture includes a 60:40 joint venture with Cipla (Aspergen Inc., USA) for biosimilars, a U.S.-based joint venture with Cipla and Manipal Education & Medical Group for cell therapy products, a strategic manufacturing partnership with RevOpsis Therapeutics for a tri-specific antibody, and a ₹1,500 million (~$25 million) capital plan to install an additional 12,000L of bioreactor capacity. Kemwell's positioning is that of an integrated, India-cost-base biologics CDMO serving regulated global markets, with its most recent commercial unlock being the October 2025 FDA clearance.

Name

Kemwell Biopharma

Legal name

Kemwell Biopharma Private Limited

Website

https://kemwellbiopharma.com

Company type

Private

Founded year

1980

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Kemwell Biopharma is a Bengaluru-based, US FDA-, EMA-, and CDSCO-accredited biologics CDMO providing integrated contract development and cGMP manufacturing services for mammalian cell-culture-based protein therapeutics to global pharmaceutical and biotech clients.

Ownership category

akta.pro rank

Product category

Biologics CDMO Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Cell Therapy CDMO (HLAGABAD), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Biologics contract manufacturing
• Biopharmaceutical CDMO services
• Mammalian cell culture manufacturing
• Drug substance manufacturing
• Fill-finish manufacturing services

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services: Kemwell operates as a pure-play biologics CDMO providing end-to-end services from cell line development to cGMP clinical and commercial manufacturing. Revenue is generated through project-based contracts with pharmaceutical and biotech companies for drug substance and drug product manufacturing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Kemwell Biopharma is a fully integrated biologics Contract Development and Manufacturing Organization (CDMO) providing end-to-end services for mammalian cell-culture based protein therapeutics. Its offerings span biologics development (process, formulation, and analytical), cGMP drug substance and drug product manufacturing, quality control/assurance, and integrated programs combining all capabilities from cell line development through commercial supply at a single Bengaluru site. Services cover monoclonal antibodies, bi-specific/multi-specific antibodies, fusion proteins, biosimilars, and cell therapies for global pharmaceutical and biotech clients.

Product overview

Kemwell Biopharma is a fully integrated biologics Contract Development and Manufacturing Organization (CDMO) providing end-to-end services for mammalian cell-culture based protein therapeutics. The company's service portfolio consists of four core offerings: Biologics Development (comprising Process Development, Formulation Development, and Analytical Development), Biologics cGMP Manufacturing (Drug Substance and Drug Product), Quality Control and Quality Assurance, and Integrated Services. The Integrated Services offering serves as the umbrella, combining all capabilities from cell line development through clinical and commercial manufacturing at a single site. The company specializes in monoclonal antibodies, bi-specific/multi-specific antibodies, fusion proteins, and cell therapies, operating facilities in Bengaluru, India with over 5000L bioreactor capacity including hybrid stainless steel and single-use bioreactor technology.

Differentiator

Problem solved

Functional benefit

Products and services

• Biologics Development Integrated development services for mammalian cell-culture based protein therapeutics including monoclonal antibodies, bi-specific/multi-specific antibodies, and fusion proteins. Encompasses process development, formulation development, and analytical development for pharmaceutical and biotech clients.
• Biologics cGMP Manufacturing FDA and EMA compliant cGMP manufacturing for drug substance and drug product using hybrid technology (stainless steel and single-use bioreactors) with over 5000L bioreactor capacity, supporting clinical and commercial production.
• Quality Control and Quality Assurance
• Integrated Services End-to-end CDMO services from cell line development through cGMP clinical and commercial manufacturing, providing a one-stop solution for mammalian cell-culture based protein therapeutics with drug substance and drug product capabilities at the same site.

Quantifiable outcome

• Batch acceptance rate: 100% for DP, >97% for DS manufacturing
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core, strategic and foundational.

• CiplacoreStrategic or Co-development Partner · 2 March 202660:40 joint venture (Cipla:Kemwell) with initial investment of up to ₹10 crore for developing, manufacturing, and commercializing biologic products and biosimilars for global markets. Cipla brings respiratory expertise and commercialization capabilities while Kemwell provides biologics manufacturing expertise. The JV was incorporated in 2022 as Aspergen Inc., USA.
• RevOpsis TherapeuticsstrategicStrategic or Co-development Partner · 17 June 2024Strategic manufacturing partnership to accelerate development of RO-104, a first-in-class tri-specific biologic for treating neovascular age-related macular degeneration. Kemwell manufactures the novel tri-specific biologic targeting VEGF-A, VEGF-C, and Ang-2 pathways. Collaboration aims to expedite therapeutic discovery to IND submission timelines.
• Manipal Education & Medical GroupcoreStrategic or Co-development Partner · 8 January 2024Joint venture in the United States with Cipla and Manipal Education & Medical Group for global development and commercialisation of innovative cell therapy products for major unmet medical needs in US, Japan, and EU regions.
• Leading German Biopharmaceutical CompanyfoundationalTechnology or IntegrationTechnology support partner for design and development of Kemwell's manufacturing facilities. Provided expertise for setting up world-class biologics manufacturing infrastructure.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• WuXi Biologics: Global #1 biologics CDMO with multi-hundred-thousand-liter bioreactor capacity, end-to-end DS/DP services, and broad geographic footprint. Competes with Kemwell for global biopharma contracts at materially larger scale.
• Samsung Biologics: One of the world's largest biologics CDMOs, headquartered in South Korea, with multi-site commercial-scale mammalian cell culture capacity and integrated DS/DP services. Direct competitor for large commercial supply contracts.
• Catalent (Novo Holdings): Global CDMO with significant biologics drug-substance and drug-product capabilities including pre-filled syringe fill-finish. Competitor for integrated biologics and fill-finish contracts at global scale.
• Lonza Biologics: Global leader in mammalian cell-culture contract manufacturing with multi-site capacity across Switzerland, US, Singapore, and Ireland. Competes with Kemwell in mAb and bi-specific manufacturing at significantly larger scale.

Direct peers

• AGC Biologics: Mid-to-large global CDMO offering mammalian cell-culture biologics development and cGMP manufacturing (drug substance and drug product) across multiple sites in US, Europe, and Japan. Comparable mid-sized competitor targeting similar biopharma outsourcing customers.
• Piramal Pharma Solutions: India-headquartered CDMO with biologics manufacturing capabilities, competing for outsourced biopharma projects in similar customer segments as Kemwell in the Indian and global markets.
• Syngene International: India-based contract development and manufacturing organization offering biologics services, including mammalian cell culture, process development, and cGMP manufacturing for global pharma/biotech. Closest Indian-headquartered, publicly-listed peer to Kemwell, competing for the same US/EU biopharma outsourcing mandates.
• Stelis Biopharma: India-based biologics CDMO offering mammalian cell-culture-based drug substance and drug product manufacturing. Direct competitor for Indian-headquartered CDMO contracts with global biopharma clients.
• Jubilant Biosys / Jubilant Pharmova: India-based contract development and biopharmaceutical manufacturing organization providing biologics CDMO services including cell-line development and cGMP manufacturing, competing for similar outsourced work.

Regional players

• Celltrion / Celltrion Pharm: South Korea-based biopharma with major in-house and contract biologics manufacturing capacity (mammalian cell culture). Indirectly competes with Kemwell for global biosimilar and biologics outsourcing mandates from Asia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/KemwellB
• LinkedInlinkedin.com/company/kemwell-pvt.-ltd.

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kemwell Biopharma